If you own pipeline, ROI, and growth performance, you probably already feel it.
As you approach an exit, every plan, budget, and result is evaluated through a question no one puts on the agenda, but everyone carries into the room....
Marketing and revenue performance are no longer judged solely on activity or short-term lift. They’re judged on whether the GTM story is scalable, whether teams are aligned to support further growth, and whether results are durable enough to support valuation.
When brand, demand, sales, and leadership narratives drift even slightly, confidence erodes fast.
Legacy DNA is led by senior operators with real exit experience.
Dr. Roxie Mooney brings doctoral-level strategic rigor and direct experience in four successful exits, including one with a multi-billion-dollar valuation. The team operates with deep fluency in the healthtech and pharmacy markets, where credibility, regulation, and evidence drive outcomes.
Our work has supported many organizations scaling from startups to mid-market growth through acquisition and exit. More importantly, we have helped growth leaders like you walk into executive, board, and diligence conversations with clarity and confidence.
You will never hesitate to bring us into the room.
We've helped leadership teams navigate four Successful exits by turning strong businesses into stories buyers recognize, trust, and value.
It’s a a focused conversation to determine whether the Growth Engine Partnership™ fits your growth stage and valuation goals.
No pitch. No pressure. Just clarity.